MINNEAPOLIS, July 23, 2014 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA), an industrial biotechnology company producing sustainable chemicals, today announced that the underwriters of its common stock offering exercised in full their option to purchase an additional 420,000 shares of common stock at the public offering price of $12.00 per share, less underwriting discounts and commissions, in connection with its previously announced underwritten public offering of 2,800,000 shares of common stock, bringing the expected net proceeds from the offering to approximately $35.8 million, after deducting expenses of BioAmber and underwriting discounts and commissions. The sale of the 2,800,000 shares closed on July 21, 2014, and the sale of the additional 420,000 shares is expected to close on July 24, 2014, subject to customary closing conditions.
Credit Suisse Securities (USA) LLC and Canaccord Genuity Inc. are acting as the bookrunning managers for the offering.
BioAmber intends to use the net proceeds of the offering for working capital and other general corporate purposes.
The securities described above were offered by BioAmber pursuant to a shelf registration statement on Form S-3 (No. 333-196470), including a base prospectus, previously filed and declared effective by the Securities and Exchange Commission (the "SEC"). A final prospectus supplement related to the offering was filed with the SEC on July 16, 2014 and is available on the SEC's website located at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the securities offered may also be obtained by contacting: Credit Suisse Securities (USA) LLC by mail at One Madison Avenue, New York, New York 10010, Attenti
|SOURCE BioAmber Inc.|
Copyright©2014 PR Newswire.
All rights reserved